167 related articles for article (PubMed ID: 24607589)
1. Bisphosphonate prodrugs: synthesis and biological evaluation in HuH7 hepatocarcinoma cells.
Monteil M; Migianu-Griffoni E; Sainte-Catherine O; Di Benedetto M; Lecouvey M
Eur J Med Chem; 2014 Apr; 77():56-64. PubMed ID: 24607589
[TBL] [Abstract][Full Text] [Related]
2. Structure-activity relationships of a new class of aromatic bisphosphonates that inhibit tumor cell proliferation in vitro.
Guenin E; Ledoux D; Oudar O; Lecouvey M; Kraemer M
Anticancer Res; 2005; 25(2A):1139-45. PubMed ID: 15868957
[TBL] [Abstract][Full Text] [Related]
3. Targeting Cancer Cells with a Bisphosphonate Prodrug.
Matsumoto K; Hayashi K; Murata-Hirai K; Iwasaki M; Okamura H; Minato N; Morita CT; Tanaka Y
ChemMedChem; 2016 Dec; 11(24):2656-2663. PubMed ID: 27786425
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and one-electron reduction characteristics of radiation-activated prodrugs possessing two 5-fluorodeoxyuridine units.
Tanabe K; Sugiura M; Ito T; Nishimoto S
Bioorg Med Chem; 2012 Sep; 20(17):5164-8. PubMed ID: 22847019
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and evaluation of N-acylamino acids derivatives of triazenes. Activation by tyrosinase in human melanoma cell lines.
Monteiro AS; Almeida J; Cabral G; Severino P; Videira PA; Sousa A; Nunes R; Pereira JD; Francisco AP; Perry MJ; Mendes E
Eur J Med Chem; 2013; 70():1-9. PubMed ID: 24125877
[TBL] [Abstract][Full Text] [Related]
6. A new cyclopamine glucuronide prodrug with improved kinetics of drug release.
Renoux B; Legigan T; Bensalma S; Chadéneau C; Muller JM; Papot S
Org Biomol Chem; 2011 Dec; 9(24):8459-64. PubMed ID: 22042246
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological studies of the thiols-triggered anticancer prodrug for a more effective cancer therapy.
Xu Y; Chen J; Li Y; Peng S; Gu X; Sun M; Gao K; Fang J
Org Biomol Chem; 2015 Mar; 13(9):2634-9. PubMed ID: 25581090
[TBL] [Abstract][Full Text] [Related]
8. New 3'-O-aromatic acyl-5-fluoro-2'-deoxyuridine derivatives as potential anticancer agents.
Szymańska-Michalak A; Wawrzyniak D; Framski G; Kujda M; Zgoła P; Stawinski J; Barciszewski J; Boryski J; Kraszewski A
Eur J Med Chem; 2016 Jun; 115():41-52. PubMed ID: 26994842
[TBL] [Abstract][Full Text] [Related]
9. New symmetrically esterified m-bromobenzyl non-aminobisphosphonates inhibited breast cancer growth and metastases.
Abdelkarim M; Guenin E; Sainte-Catherine O; Vintonenko N; Peyri N; Perret GY; Crepin M; Khatib AM; Lecouvey M; Di Benedetto M
PLoS One; 2009; 4(3):e4685. PubMed ID: 19262688
[TBL] [Abstract][Full Text] [Related]
10. Potent inhibitors of phosphatidylinositol 3 (PI3) kinase that have antiproliferative activity only when delivered as prodrug forms.
O'Brien NJ; Amran S; Medan J; Cleary B; Deady LW; Jennings IG; Thompson PE; Abbott BM
ChemMedChem; 2013 Jun; 8(6):914-8. PubMed ID: 23568455
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and biological activity of N-2,3-dihydroxypropyl-N-4-chlorobutyl nucleoside phosphoramidate prodrugs.
Wu W; Borch RF
Mol Pharm; 2006; 3(4):451-6. PubMed ID: 16889439
[TBL] [Abstract][Full Text] [Related]
12. PMPA and PMEA prodrugs for the treatment of HIV infections and human papillomavirus (HPV) associated neoplasia and cancer.
Pertusati F; Hinsinger K; Flynn ÁS; Powell N; Tristram A; Balzarini J; McGuigan C
Eur J Med Chem; 2014 May; 78():259-68. PubMed ID: 24686012
[TBL] [Abstract][Full Text] [Related]
13. Extended scaffold glucuronides: en route to the universal synthesis of O-aryl glucuronide prodrugs.
Walther R; Jarlstad Olesen MT; Zelikin AN
Org Biomol Chem; 2019 Jul; 17(29):6970-6974. PubMed ID: 31290904
[TBL] [Abstract][Full Text] [Related]
14. Methylenebisphosphonates with dienone pharmacophore: synthesis, structure, antitumor and fluorescent properties.
Makarov MV; Leonova ES; Rybalkina EY; Khrustalev VN; Shepel NE; Röschenthaler GV; Timofeeva TV; Odinets IL
Arch Pharm (Weinheim); 2012 May; 345(5):349-59. PubMed ID: 22213431
[TBL] [Abstract][Full Text] [Related]
15. Synthesis and antiproliferative activity of aromatic and aliphatic bis[aminomethylidene(bisphosphonic)] acids.
Goldeman W; Nasulewicz-Goldeman A
Bioorg Med Chem Lett; 2014 Aug; 24(15):3475-9. PubMed ID: 24928399
[TBL] [Abstract][Full Text] [Related]
16. A dual-targeting hybrid platinum(IV) prodrug for enhancing efficacy.
Xiao H; Yan L; Zhang Y; Qi R; Li W; Wang R; Liu S; Huang Y; Li Y; Jing X
Chem Commun (Camb); 2012 Nov; 48(87):10730-2. PubMed ID: 23012698
[TBL] [Abstract][Full Text] [Related]
17. Activity of nitrogen-containing and non-nitrogen-containing bisphosphonates on tumor cell lines.
Zhang Y; Leon A; Song Y; Studer D; Haase C; Koscielski LA; Oldfield E
J Med Chem; 2006 Sep; 49(19):5804-14. PubMed ID: 16970405
[TBL] [Abstract][Full Text] [Related]
18. Prodrug-inspired probes selective to cathepsin B over other cysteine cathepsins.
Chowdhury MA; Moya IA; Bhilocha S; McMillan CC; Vigliarolo BG; Zehbe I; Phenix CP
J Med Chem; 2014 Jul; 57(14):6092-104. PubMed ID: 24940640
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and biological evaluations of a monomethylauristatin E glucuronide prodrug for selective cancer chemotherapy.
Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Jayle C; Alsarraf J; Thomas M; Papot S
Eur J Med Chem; 2013 Sep; 67():75-80. PubMed ID: 23845743
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of a new bisphosphonate, minodronate, on proliferation and invasion of a variety of malignant bone tumor cells.
Kubo T; Shimose S; Matsuo T; Tanaka K; Yasunaga Y; Sakai A; Ochi M
J Orthop Res; 2006 Jun; 24(6):1138-44. PubMed ID: 16705696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
